NASDAQ:ATRAAtara Biotherapeutics Stock Price, Forecast & News

Atara Biotherapeutics' stock was trading at $9.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ATRA shares have increased by 15.5% and is now trading at $11.50. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Atara Biotherapeutics.

Atara Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Atara Biotherapeutics.

Atara Biotherapeutics Inc (NASDAQ:ATRA) announced its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($1.20) earnings per share for the quarter, beating analysts' consensus estimates of ($1.41) by $0.21. View Atara Biotherapeutics' earnings history.

9 brokerages have issued 12 month price targets for Atara Biotherapeutics' shares. Their forecasts range from $9.00 to $70.00. On average, they expect Atara Biotherapeutics' share price to reach $29.38 in the next twelve months. This suggests a possible upside of 155.4% from the stock's current price. View analysts' price targets for Atara Biotherapeutics.

Media coverage about ATRA stock has been trending negative this week, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Atara Biotherapeutics earned a news sentiment score of -2.5 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAtara Biotherapeutics.

Atara Biotherapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 11,980,000 shares, an increase of 17.1% from the April 30th total of 10,230,000 shares. Based on an average daily trading volume, of 855,700 shares, the short-interest ratio is currently 14.0 days. Approximately 22.8% of the shares of the company are sold short. View Atara Biotherapeutics' Current Options Chain.

Some companies that are related to Atara Biotherapeutics include Novavax (NVAX), Alector (ALEC), Fate Therapeutics (FATE), Bill.com (RVMD), Adverum Biotechnologies (ADVM), SpringWorks Therapeutics (SWTX), Sangamo Therapeutics (SGMO), Twist Bioscience (TWST), Mesoblast (MESO), Editas Medicine (EDIT), Adaptimmune Therapeutics (ADAP), Regenxbio (RGNX), I-Mab (BDTX), Cortexyme (CRTX) and Coherus Biosciences (CHRS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include Crispr Therapeutics (CRSP), AbbVie (ABBV), Gilead Sciences (GILD), Micron Technology (MU), Amarin (AMRN), Editas Medicine (EDIT), Exelixis (EXEL), Karyopharm Therapeutics (KPTI), Advanced Micro Devices (AMD) and ImmunoGen (IMGN).

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Atara Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (8.98%), Maverick Capital Ltd. (8.82%), BlackRock Inc. (7.74%), Morgan Stanley (5.87%), Morgan Stanley (5.87%) and Federated Hermes Inc. (4.90%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Eric Dobmeier, Isaac E Ciechanover, Joe Newell, Joel S Marcus and Utpal Koppikar. View institutional ownership trends for Atara Biotherapeutics.

ATRA stock was sold by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Wasatch Advisors Inc., Two Sigma Investments LP, Wells Fargo & Company MN, AXA, UBS Group AG, BlackRock Inc., and Vident Investment Advisory LLC. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Joe Newell, and Utpal Koppikar. View insider buying and selling activity for Atara Biotherapeutics.

ATRA stock was acquired by a variety of institutional investors in the last quarter, including Redmile Group LLC, Federated Hermes Inc., Morgan Stanley, Morgan Stanley, Maverick Capital Ltd., JPMorgan Chase & Co., FDx Advisors Inc., and FDx Advisors Inc.. Company insiders that have bought Atara Biotherapeutics stock in the last two years include Eric Dobmeier, and Utpal Koppikar. View insider buying and selling activity for Atara Biotherapeutics.

Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ATRA stock can currently be purchased for approximately $11.50.

Atara Biotherapeutics has a market capitalization of $677.93 million. The biotechnology company earns $-290,980,000.00 in net income (profit) each year or ($5.67) on an earnings per share basis. Atara Biotherapeutics employs 321 workers across the globe.

The official website for Atara Biotherapeutics is www.atarabio.com.

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.